1. RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON‐2 TRIAL. (12th June 2019) Authors: Illidge, T.; Horwitz, S.; Iyer, S.; Bartlett, N.; Kim, W.; Tilly, H.; Belada, D.; Feldman, T.; Illés, Á.; Jacobsen, E.; Hüttmann, A.; Zinzani, P.; O'Connor, O.A.; Trepicchio, W.; Miao, H.; Rao, S.; Onsum, M.; Manley, T.; Advani, R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PHASE 1B/2 STUDY OF ORAL NANATINOSTAT (N) AND VALGANCICLOVIR (VG) IN SUBJECTS WITH EPSTEIN‐BARR VIRUS (EBV)‐ASSOCIATED LYMPHOMAS. (12th June 2019) Authors: Porcu, P.; Haverkos, B.; Brem, E.; Vallurupalli, A.; Feldman, T.; Alpdogan, O.; Brammer, J.; Bryan, L.J.; Barta, S.; Schriefer, A.; Obrzut, S.; Shen, H.; Rochford, R.; Baiocchi, R.; Casper, C.; Gutheil, J.; Melink, T.; Kearns, C.; Burner, D.; McRae, R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T‐CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE. (June 2017) Authors: Oki, Y.; Feldman, T.; Chihara, D.; Sanchez, L.; Fanale, M.; Connors, J.M.; Wong, S.; Savage, K.J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2‐YEAR FOLLOW‐UP. (12th June 2019) Authors: Ansell, S.; Ramchandren, R.; Domingo‐Domènech, E.; Rueda, A.; Trněný, M.; Feldman, T.; Lee, H.; Provencio, M.; Sillaber, C.; Cohen, J.; Savage, K.; Willenbacher, W.; Sumbul, A.; Sacchi, M.; Armand, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL). (23rd June 2022) Authors: Carlo-Stella, C.; Ansell, S.; Zinzani, P. L; Radford, J.; Maddocks, K.; Pinto, A.; Collins, G. P.; Bachanova, V.; Bartlett, N.; Bence-Bruckler, I.; Hamadani, M.; Kline, J.; Mayer, J.; Savage, K. J.; Advani, R.; Caimi, P.; Casasnovas, R.-O.; Feldman, T.; Hess, B.; Bastos-Oreiro, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The evolution of leukaemia from pre‐leukaemic and leukaemic stem cells. (29th January 2021) Authors: Shlush, L. I.; Feldman, T. Journal: Journal of internal medicine Issue: Volume 289:Number 5(2021) Page Start: 636 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗